MiR-145 participates in the modulation of proliferation and invasion by targeting FSCN1 in various cancers, including bladder cancer, oesophageal squamous cell carcinoma, prostate cancer, melanoma cells and breast cancer cells 91,133–138. Here, FSCN1 is linked to prostate carcinoma.